Header BackgroundLIXTE Logo

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)

Lixte is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies including cytotoxic drugs, radiation, and immune checkpoint blockers.

LB-100 may be a true game changer in cancer treatment.

Protein phosphatases are ubiquitous enzymes that regulate many signaling networks important to cell growth, division and death. These enzymes, especially protein phosphatase 2A (PP2A), have long been appreciated as potentially important targets for anti-cancer drugs, but, because of their multi-functionality, it has been believed that their inhibition would be too toxic for clinical use. Lixte has shown that this is not the case. In a Phase 1 clinical trial, LB-100, an inhibitor of PP2A, was well tolerated at doses associated with significant tumor shrinkage (objective regression) and/or the arrest of tumor progression in patients with advancing cancers.

LB-100 has been shown to inhibit a spectrum of human cancers that have abnormalities in PP2A function.

In extensive preclinical studies, LB-100, when coupled with standard cytotoxic drug and/or radiation therapies, potentiates the effectiveness of such regimens against hematologic cancers and solid tumors without enhancing toxicity. In addition, as recently shown, low doses of LB-100 significantly increase the effectiveness of PD-1 immune-checkpoint blockade by activating cytotoxic T cells and CAR-T cells. The addition of LB-100 may be a breakthrough way to enhance the effectiveness of anticancer immunotherapy with both anti-PD-1 and anti-CTLA-4 drugs.

Our immediate goal is to demonstrate the clinical therapeutic benefit of LB-100 in major cancers that affect the largest populations.

Our focus is on cancers that are vulnerable to the inhibition of PP2A as an effective treatment based on molecular and in vivo animal data. Our pipeline includes a Phase 1b/2 trial of LB-100 in myelodysplastic syndrome in progress at the Moffitt Cancer Center in Tampa, FL (NCT03886662) and a Phase 1b/randomized 2 trial of doxorubicin with and without LB-100 in first line advanced soft tissue sarcoma in Spain led by the Spanish Sarcoma Group (Grupo Español de Investigación en Sarcomas, or GEIS). In addition, the National Cancer Institute has initiated a clinical pharmacologic study (NCT03027388) of LB-100 to determine the extent of penetration of recurrent brain tumors. If positive, several centers wish to evaluate LB-100 plus standard therapy in patients with glioblastoma multiforme, the most common and deadly of adult brain cancers. Recently, we announced an agreement on a Phase 1b clinical trial with City of Hope, a world-renowned independent cancer research and treatment center. The trial (NCT04560972) will assess the combination of LB-100 with a standard regimen for untreated, extensive stage-disease small cell lung cancer (ED-SCLC).

In addition to cancers, there is another intriguing possible use of LB-100 in genetic disorders.

LB-100 may be an effective treatment for the symptoms of a rare genetic disorder called Angelman Syndrome (AS), affecting about 20,000 persons in the US and 500,000 worldwide. A group of neuroscientists in China and Japan recently reported that LB-100 improved muscle strength, movement coordination, and learning in a mouse model of AS. This is a completely unanticipated finding. Lixte has entered into an agreement with the Foundation for Angelman Syndrome Therapeutics (FAST) to collaborate in supporting preclinical studies at The University of California, Davis to verify the apparent benefit of LB-100 in a mouse model of AS. If LB-100 reduces AS signs in the rodent model, FAST and Lixte have agreed to discuss further collaboration to assess the potential benefit of LB-100 in patients with AS.

Header Background

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)

Lixte is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies including cytotoxic drugs, radiation, and immune checkpoint blockers.

LB-100 may be a true game changer in cancer treatment.

Protein phosphatases are ubiquitous enzymes that regulate many signaling networks important to cell growth, division and death. These enzymes, especially protein phosphatase 2A (PP2A), have long been appreciated as potentially important targets for anti-cancer drugs, but, because of their multi-functionality, it has been believed that their inhibition would be too toxic for clinical use. Lixte has shown that this is not the case. In a Phase 1 clinical trial, LB-100, an inhibitor of PP2A, was well tolerated at doses associated with significant tumor shrinkage (objective regression) and/or the arrest of tumor progression in patients with advancing cancers.

LB-100 has been shown to inhibit a spectrum of human cancers that have abnormalities in PP2A function.

In extensive preclinical studies, LB-100, when coupled with standard cytotoxic drug and/or radiation therapies, potentiates the effectiveness of such regimens against hematologic cancers and solid tumors without enhancing toxicity. In addition, as recently shown, low doses of LB-100 significantly increase the effectiveness of PD-1 immune-checkpoint blockade by activating cytotoxic T cells and CAR-T cells. The addition of LB-100 may be a breakthrough way to enhance the effectiveness of anticancer immunotherapy with both anti-PD-1 and anti-CTLA-4 drugs.

Our immediate goal is to demonstrate the clinical therapeutic benefit of LB-100 in major cancers that affect the largest populations.

Our focus is on cancers that are vulnerable to the inhibition of PP2A as an effective treatment based on molecular and in vivo animal data. Our pipeline includes a Phase 1b/2 trial of LB-100 in myelodyplastic syndrome in progress at the Moffitt Cancer Center in Tampa, FL (NCT03886662) and a Phase 1b/randomized 2 trial of doxorubicin with and without LB-100 in first line advanced soft tissue sarcoma in Spain led by the Spanish Sarcoma Group (Grupo Español de Investigación en Sarcomas, or GEIS), to open in 2021. In addition, the National Cancer Institute has initiated a clinical pharmacologic study (NCTO30227388) of LB-100 to determine the extent of penetration of recurrent brain tumors. If positive, several centers wish to evaluate LB-100 plus standard therapy in patients with glioblastoma multiforme, the most common and deadly of adult brain cancers. Recently, we announced an agreement on a Phase 1b clinical trial with City of Hope, a world-renowned independent cancer research and treatment center. The trial, expected to begin in 2021, will assess the combination of LB-100 with a standard regimen for untreated, extensive stage-disease small cell lung cancer (ED-SCLC).

In addition to cancers, there is another intriguing possible use of LB-100 in genetic disorders.

LB-100 may be an effective treatment for the symptoms of a rare genetic disorder called Angelman Syndrome (AS), affecting about 20,000 persons in the US and 500,000 worldwide. A group of neuroscientists in China and Japan recently reported that LB-100 improved muscle strength, movement coordination, and learning in a mouse model of AS. This is a completely unanticipated finding. Lixte has entered into an agreement with the Foundation for Angelman Syndrome Therapeutics (FAST) to collaborate in supporting preclinical studies at The University of California, Davis to verify the apparent benefit of LB-100 in a mouse model of AS. If LB-100 reduces AS signs in the rodent model, FAST and Lixte have agreed to discuss further collaboration to assess the potential benefit of LB-100 in patients with AS.

Header Background

Dedicated to Creating Better Treatments for Cancer

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)

Lixte is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies including cytotoxic drugs, radiation, and immune checkpoint blockers.

LB-100 may be a true game changer in cancer treatment.

Protein phosphatases are ubiquitous enzymes that regulate many signaling networks important to cell growth, division and death. These enzymes, especially protein phosphatase 2A (PP2A), have long been appreciated as potentially important targets for anti-cancer drugs, but, because of their multi-functionality, it has been believed that their inhibition would be too toxic for clinical use. Lixte has shown that this is not the case. In a Phase 1 clinical trial, LB-100, an inhibitor of PP2A, was well tolerated at doses associated with significant tumor shrinkage (objective regression) and/or the arrest of tumor progression in patients with advancing cancers.

LB-100 has been shown to inhibit a spectrum of human cancers that have abnormalities in PP2A function.

In extensive preclinical studies, LB-100, when coupled with standard cytotoxic drug and/or radiation therapies, potentiates the effectiveness of such regimens against hematologic cancers and solid tumors without enhancing toxicity. In addition, as recently shown, low doses of LB-100 significantly increase the effectiveness of PD-1 immune-checkpoint blockade by activating cytotoxic T cells and CAR-T cells. The addition of LB-100 may be a breakthrough way to enhance the effectiveness of anticancer immunotherapy with both anti-PD-1 and anti-CTLA-4 drugs.

Our immediate goal is to demonstrate the clinical therapeutic benefit of LB-100 in major cancers that affect the largest populations.

Our focus is on cancers that are vulnerable to the inhibition of PP2A as an effective treatment based on molecular and in vivo animal data. Our pipeline includes a Phase 1b/2 trial of LB-100 in myelodyplastic syndrome in progress at the Moffitt Cancer Center in Tampa, FL (NCT03886662) and a Phase 1b/randomized 2 trial of doxorubicin with and without LB-100 in first line advanced soft tissue sarcoma in Spain led by the Spanish Sarcoma Group (Grupo Español de Investigación en Sarcomas, or GEIS), to open in 2021. In addition, the National Cancer Institute has initiated a clinical pharmacologic study (NCTO30227388) of LB-100 to determine the extent of penetration of recurrent brain tumors. If positive, several centers wish to evaluate LB-100 plus standard therapy in patients with glioblastoma multiforme, the most common and deadly of adult brain cancers. Recently, we announced an agreement on a Phase 1b clinical trial with City of Hope, a world-renowned independent cancer research and treatment center. The trial, expected to begin in 2021, will assess the combination of LB-100 with a standard regimen for untreated, extensive stage-disease small cell lung cancer (ED-SCLC).

In addition to cancers, there is another intriguing possible use of LB-100 in genetic disorders.

LB-100 may be an effective treatment for the symptoms of a rare genetic disorder called Angelman Syndrome (AS), affecting about 20,000 persons in the US and 500,000 worldwide. A group of neuroscientists in China and Japan recently reported that LB-100 improved muscle strength, movement coordination, and learning in a mouse model of AS. This is a completely unanticipated finding. Lixte has entered into an agreement with the Foundation for Angelman Syndrome Therapeutics (FAST) to collaborate in supporting preclinical studies at The University of California, Davis to verify the apparent benefit of LB-100 in a mouse model of AS. If LB-100 reduces AS signs in the rodent model, FAST and Lixte have agreed to discuss further collaboration to assess the potential benefit of LB-100 in patients with AS.